Systemic effects of oral budesonide in hematopoietic transplant: Implications of drug interaction with azoles

Bone Marrow Transplantation

Volumn 47, Issue 10, 2012, Pages 1370-1371

  El Fakih, R ^a   Obi, G A ^b   Scholoff, A ^b   Carrum, G ^b   Kamble, R T ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; FLUCONAZOLE; HYDROCORTISONE; INFLIXIMAB; PREDNISONE; RITUXIMAB; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CENTRAL OBESITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CUSHING SYNDROME; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; GLUCOSE INTOLERANCE; HUMAN; HYDROCORTISONE BLOOD LEVEL; INTESTINE; LETTER; LIVER; MALE; MEDICAL RECORD REVIEW; MOOD CHANGE; MOON FACE; MYCOSIS; OBESITY; PRIORITY JOURNAL; SIDE EFFECT; SKIN; WEIGHT GAIN;

ADMINISTRATION, ORAL; AGED; ANTI-INFLAMMATORY AGENTS; AZOLES; BUDESONIDE; CUSHING SYNDROME; DRUG INTERACTIONS; FEMALE; GASTROINTESTINAL DISEASES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IATROGENIC DISEASE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 84867400031     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.17     Document Type: Letter

References (10)

1. Weisdorf DJ, Snover DC, Haake R, Miller WJ, McGlave PB, Blazar B et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990; 76: 624-629.
2. Baehr PH, Levine DS, Bouvier ME, Hockenbery DM, Gooley TA, Stern JG et al. Oral beclomethasone dipropionate for treatment of human intestinal graft-versus-host disease. Transplantation 1995; 60: 1231-1238.
3. Bertz H, Afting M, Kreisel W, Duffner U, Greinwald R, Finke J. Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD. Bone Marrow Transplant 1999; 24: 1185-1189.
4. Ibrahim RB, Abidi MH, Cronin SM, Lum LG. Nonabsorbable corticosteroids use in the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 2009; 15: 395-405.
5. Hockenbery DM, Cruickshank S, Rodell TC, Gooley T, Schuening F, Rowley S et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007; 109: 4557-4563.
6. Elad S, Zeevi I, Finke J, Koldehoff M, Schwerdtfeger R, Wolff D et al. Improvement in oral chronic graft-versus-host disease with the administration of effervescent tablets of topical budesonide-an open, randomized, multicenter study. Biol Blood Marrow Transplant 2011; 18: 134-140.
7. Budesonide (Package Insert). Prometheus Laboratories Inc: San Diego, CA, 2009.
8. Frankel JK, Packer CD. Cushing's syndrome due to antiretroviral- budesonide interaction. Ann Pharmacother 2011; 45: 823-824.
9. De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J Cyst Fibros 2003; 2: 72-75.
10. Hofer KN. Oral budesonide in the management of Crohn's disease. Ann Pharmacother 2003; 37: 1457-1464.